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Introduction: Cutaneous silent period (CSP) is an inhibitory spinal protective refl ex and its 
afferents consist of A-delta nerve fi bers. We aimed to evaluate patients with fi bromyalgia 
(FM) and healthy controls to determine any differences between the groups in terms of CSP 
duration and latency, and if present, to determine whether there is any relationship with 
disease characteristics, psychological disorders and quality of life. 
Materials and methods: Thirty-two patients with FM and 32 healthy volunteers were includ-
ed in the study. The patient and control groups were compared in terms of CSP latency and 
duration in both upper and lower extremities. Disease characteristics, psychological disor-
ders and quality of life of patients were assessed using the Fibromyalgia Impact Question-
naire (FIQ) and Short Form-36 (SF-36). Patients with CSP measurements equal to or lower 
than those of the control group were compared with those with higher values than controls 
in terms of disease characteristics, psychological status and quality of life. 
Results: Signifi cantly prolonged CSP latencies in both upper and lower extremities were 
determined in patients compared to controls. We found that prolongation of CSP latency in 
the lower extremity is associated with disease severity and functional disability. 
Conclusions: CSP latencies in both upper and lower extremities in patients with FM are lon-
ger than in healthy volunteers. Moreover, prolongation of CSP latency in the lower extrem-
ity is associated with disease severity and physical functional disability.
© 2013 Elsevier Editora Ltda. All rights reserved.
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Importância do período de silêncio cutâneo na fi bromialgia e sua relação 
com as características da doença, distúrbios psicológicos e qualidade de 
vida dos pacientes 
Palavras-chave:
Fibromialgia
Período de silêncio cutâneo 
Defi ciência
r e s u m o
Introdução: O período de silêncio cutâneo (PSC) é um refl exo protetor inibitório da coluna 
vertebral e seus aferentes consistem em fi bras nervosas A-delta. Nosso objetivo foi avaliar 
pacientes com fi bromialgia (FM) e controles saudáveis para determinar as diferenças entre 
os grupos em relação à duração e latência do PSC, e quando presente, determinar se há al-
guma relação com as características da doença, distúrbios psicológicos e qualidade de vida. 
Materiais e métodos: Trinta e dois pacientes com FM e 32 voluntários saudáveis foram in-
cluídos no estudo. Os dois grupos foram comparados em relação à latência e duração do 
PSC em ambos os membros superiores e inferiores. Características da doença, distúrbios 
psicológicos e qualidade de vida dos pacientes foram avaliados utilizando o Fibromyalgia 
Impact Questionnaire (FIQ), e o Short Form-36 (SF-36). Os pacientes com medida de PSC igual 
ou inferior às do grupo controle foram comparados com aqueles com valores mais elevados 
do que os controles em termos de características da doença, estado psicológicos e quali-
dade de vida. 
Resultados: Latências signifi cativamente prolongadas de PSC nos membros superiores e in-
feriores foram determinadas em pacientes comparados com os controles. Observou-se que 
a prolongamento da latência do PSC no membro inferior estava associado com a gravidade 
da doença e incapacidade funcional.
Conclusões: Latências do PCS nos membros superiores e inferiores em pacientes com FM 
são mais longas do que em voluntários saudáveis. Além disso, o prolongamento da latên-
cia do PSC no membro inferior está associado com a gravidade da doença e incapacidade 
funcional física.
© 2013 Elsevier Editora Ltda. Todos os direitos reservados.
Introduction
Fibromyalgia (FM) is a chronic pain syndrome characterized 
by widespread pain and tender points at specifi c anatomic 
areas that cannot be understood regarding its etiology, de-
spite all the new developments.1 Some symptoms and signs, 
including chronic fatigue, headache, sleep disturbance, psy-
chological disorders, irritable bowel and bladder syndromes, 
dysmenorrhea, sensory disorders such as paraesthesia and 
dysesthesia without neuropathy, and Raynaud’s phenom-
enon, are common in FM.1,2
Although the etiopathogenesis is not yet fully elucidated, 
studies have reported that various factors might be effective, 
such as neuroendocrine and autoimmune dysfunction and 
genetic predisposition.3 Further, studies have shown that hy-
perexcitability of spinal and supraspinal neurons in FM play 
an important role in the development and maintenance of 
chronic pain.4,5 
Studies that used the nociceptive fl exion refl ex (NFR) to 
show the excitability of dorsal horn neurons of the spinal 
cord, which formed with peripheral C fi bers (a nociceptive af-
ferent), have reported that this excitability in patients with 
FM causes central sensitization and chronic pain.6,7
The assessment method of the A-delta fi ber (the other no-
ciceptive afferent) is the cutaneous silent period (CSP).8 The 
NFR and CSP are the excitatory and inhibitory parts of the 
same spinal protective refl ex, respectively.9 Although the CSP 
has been measured in various muscles using different meth-
ods, there is only one study10 in the literature, and only the 
upper extremity was evaluated in that study. To our knowl-
edge, no study in the literature has evaluated the relationship 
between CSP and disease duration, pain level, numbers of to-
tal symptoms and tender points, severity of FM, psychological 
disorders, and quality of life.
Therefore, we aimed to compare patients with FM and 
healthy controls to determine any difference in CSP duration 
and latency in the upper and lower extremities, and if pres-
ent, to determine whether there is any relationship between 
CSP and disease characteristics, psychological disorders and 
quality of life.
Materials and methods
Study population 
Thirty-two patients who were admitted to the Physical Medi-
cine and Rehabilitation Clinic and were diagnosed with FM 
according to the American College of Rheumatology (ACR) 
1990 classifi cation criteria were included in the study.1 Thirty-
two healthy volunteers consisting of hospital staff and rela-
tives of patients were included in the study as controls. 
Exclusion criteria for patients and volunteers were as 
follows: presence of any central and/or peripheral neuro-
logic disease such as peripheral neuropathy, radiculopathy 
or multiple sclerosis, muscle disease such as infl ammatory 
myopathy or myositis, any infl ammatory, endocrine, cardiac, 
or psychiatric disease, osteoarthritis, trauma of the hand or 
foot, tenosynovitis, or a history of surgery. Those who were 
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pregnant or lactating or who had used any psychotropic and/
or antihistamine drugs in the last month were also excluded 
from the study. 
Patients and volunteers with normal musculoskeletal and 
neurologic examinations including range of motion, muscle 
strength, superfi cial sensation, and deep tendon refl ex, and 
who had normal laboratory parameters including complete 
blood count, complete urinalysis, erythrocyte sedimentation 
rate, vitamin B12, thyroid function tests, and biochemical 
tests including electrolytes and enzymes of liver, kidney and 
muscle were included in the study.
Patients and volunteers were informed about the study 
and their written consents were obtained at the start of the 
study. The study was approved by the local Ethical Board and 
was performed in accordance with the principles of the Dec-
laration of Helsinki.
Electrophysiologic tests 
Electrophysiologic evaluations were performed in the electro-
physiology laboratory of Gülhane Military Medical Academy 
Department of Neurology using a 2+8 channel electromyo-
gram (EMG) device (MEDELEC Synergy-Oxford, U.K.) and ac-
cording to the protocol described by Oh.11 The room tempera-
ture was 24 ± 1°C, and the skin temperature of patients and 
volunteers was over 32°C. While measurements of the upper 
extremity were applied in the sitting position, measurements 
of the lower extremity were applied in the supine position.
Nerve conduction tests
Sensory nerve conduction tests were evaluated from the right 
median, left ulnar and right sural nerves. Motor nerve con-
duction tests were evaluated from the right median, left ul-
nar, right peroneal, and left tibial nerves. Distal motor latency 
(DML) (ms) and motor conduction velocity (MCV) in motor 
nerves and sensory conduction velocity (SCV) (m/s) in sensory 
nerves were recorded. 
CSP investigations
Sensory nerves were stimulated in the lower extremity using 
bar electrode and in the upper extremity using ring electrode. 
First, the sensory threshold was found. For this purpose, an 
electrical current of 0.5 ms duration starting from an inten-
sity of 0.6 mA was performed laterally to the lateral malleolus 
in the lower extremity and to the second fi nger of the up-
per extremity. The lowest intensity, which was determined 
by gradually increasing the intensity until it was felt by the 
individual, was recorded as the sensory intensity threshold. 
CSP measurements were performed in the right upper and 
lower extremities using the abductor pollicis brevis (APB) and 
tibialis anterior (TA) muscles, respectively. The second fi nger 
in the right upper extremity was stimulated, and recordings 
were obtained from the APB muscle. Before the recording, the 
patient was asked to perform thumb abduction with maximal 
effort, and the maximal motor unit action potential (MUAP) 
amplitude was measured on the screen. Subjects were asked 
to perform thumb abduction with MUAP amplitudes of at 
least 25% of the maximal MUAP amplitude. While the patient 
was constantly performing this abduction, the median nerve 
was stimulated at an intensity of 15 times the sensory thresh-
old. Five recordings were obtained at 30-second intervals. The 
CSP latency and duration were measured by assessing the av-
erage of 5 traces. The endpoint at which an observable clear-
cut inhibition in muscle activity started was considered as the 
CSP latency (ms). The CSP duration (ms) was determined by 
measuring the time between the point of inhibition of muscle 
activity and the point at which it started to return to baseline 
muscle activity. The sural nerve was stimulated superfi cially 
laterally to the lateral malleolus in the right lower extremity, 
and recordings were obtained from the TA muscle by using 
the same method described above.
Clinical tests
Disease characteristics including disease duration, symp-
toms associated with FM and pain level were questioned. The 
numbers of tender points and symptoms were recorded. To-
tal numbers of symptoms were calculated and recorded. The 
general pain level felt in the last 48 hours was assessed by 
visual analogue scale (VAS) with 0-10 cm.
To assess severity of disease, functional disability and spe-
cifi c quality of life, the Fibromyalgia Impact Questionnaire 
(FIQ)12 was used, according to which the total score was evalu-
ated between 0-100, with a higher score showing a greater im-
pact of the syndrome on the person.
To assess possible depression symptoms of the patients, 
the Beck Depression Inventory (BDI)13 was used, and to as-
sess anxiety symptoms, the Beck Anxiety Inventory (BAI)14 
was used. Twenty-one Likert-type questions were asked with 
these scales, and each question was evaluated between 0-3.
The general quality of life of patients was evaluated with 
Short Form-36 (SF-36).15 Accordingly, two sub-group scores 
were created as physical health and mental health. The total 
score was evaluated between 0-100.
Abbreviations
FM:  fi bromyalgia
NFR:  nociceptive fl exion refl ex
CSP:  cutaneous silent period
EMG:  electromyogram
DML:  Distal motor latency
MCV:  motor conduction velocity
SCV:  sensory conduction velocity
APB:  abductor pollicis brevis
TA:  tibialis anterior
MUAP:  motor unit action potential
VAS:  Visual Analogue Scale
FIQ:  Fibromyalgia Impact Questionnaire
BDI:  Beck Depression Inventory
BAI:  Beck Anxiety Inventory
SF-36:  Short Form-36
SPSS:  Statistical Package for the Social Sciences
OR:  odds ratio
HPA:  hypothalamic-pituitary-adrenal
NMDA:  N-methyl-D-aspartic acid
CNS:  central nervous system
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Comparisons
The patient and control groups were compared in terms of 
CSP latency and duration in the upper and lower extremities. 
Sub-groups were formed according to the CSP latency and 
duration levels that were determined to be signifi cantly dif-
ferent between groups on the basis of the CSP mean of the 
control group. Patients with CSP measurements equal to or 
below values of the control group (group 1) were compared 
to patients with CSP measurements above the values of the 
control group (group 2) in terms of disease duration, number 
of total symptoms and tender points, pain level evaluated by 
VAS, FIQ score, levels of depression and anxiety, and quality 
of life. 
Statistical analysis
Data analyses were made using the Statistical Package for the 
Social Sciences (SPSS Inc., USA) 11.5 for Windows. Descrip-
tive statistics were shown as mean ± standard deviation and 
median for continuous variables and observation number (%) 
for nominal variables using chi-square tests. Statistically sig-
nifi cant differences between groups in terms of continuous 
variables were studied with Mann-Whitney U test (according 
to Kolmogorov-Smirnov test, continuous variables were not 
the distribution normal) and nominal variables with Pearson 
chi-square test. Signifi cance of the difference in variables be-
tween groups 1 and 2 was analyzed using Pearson chi-square 
test. Regression analysis was used for signifi cant correlations 
by using group 1 values as the dependent variable. Values of P 
< 0.05 were considered as statistically signifi cant. 
Results
The median age of the 64 participants included in the study 
(46 [71.9%] females, 18 [28.1%] males) was 41.00 (38.53 ± 8.02) 
years. The distribution and comparison of demographic char-
acteristics and motor and sensory nerve conduction values of 
patients (n = 32) and volunteers (n = 32) according to groups 
are presented in Table 1. There was no signifi cant difference 
between groups in terms of age, gender and motor and sen-
sory conduction values (P > 0.05). 
The distribution and comparison of CSP latency and dura-
tion measured from the APB and TA muscles of patients and 
controls according to groups are shown in Table 2.
While the mean CSP latencies in the upper and lower ex-
tremities of patients were 87.25 and 107.75 ms and CSP dura-
tions were 46.25 and 51.15 ms, respectively, these values in 
controls were 80.75 and 101.62 ms (latencies) and 48.75 and 
54.50 ms (durations), respectively.
Signifi cantly prolonged CSP latencies in both upper and 
lower extremities were determined in patients compared to 
the control group (P < 0.05).
The distribution of disease duration, numbers of total 
symptoms and tender points, VAS level, FIQ score, levels of 
depression and anxiety, and quality of life of patients are pre-
sented in Table 3.
With respect to sub-groups formed according to mean 
CSP latency of the control group (patients with equal/lower 
values versus higher values compared to controls), it was 
found that while the number of patients with normal CSP 
latency in the upper extremity (group 1 for upper extremity) 
was 4 (12.5%), the number of patients with normal latency 
in the lower extremity (group 1 for lower extremity) was 12 
(37.5%).
The comparisons between group 1 and group 2 for upper 
and lower extremities in terms of disease duration, numbers 
of total symptoms and tender points, pain level evaluated by 
VAS, FIQ score, levels of depression and anxiety, and quality of 
life are shown in Tables 4 and 5. 
Table 1 – Distribution and comparison of demographic 
characteristics and motor and sensory nerve conduction 
values of patients and volunteers according to groups.
Patient group 
(n = 32) 
n(%),  mean ± SD
Control group  
(n = 32) 
n(%),  mean ± SD
P
Age (year) 39.59 ± 7.03 37.47 ± 8.89 0.293
Gender
Female
Male
26 (81.3)
6 (18.7)
20 (62.5)
12 (37.5)
0.098
Right median 
nerve DML (ms)
2.57 ± 0.18 2.43 ± 0.37 0.069
Right median 
nerve MCV (m/s)
59.32 ± 3.23 59.48 ± 4.36 0.871
Left ulnar nerve 
DML (ms)
2.21 ± 0.18 2.14 ± 0.33 0.982
Left ulnar nerve 
MCV (m/s)
68.30 ± 10.59 64.75 ± 9.60 0.165
Right peroneal 
nerve DML (ms)
3.45 ± 0.72 3.67 ± 0.81 0.262
Right peroneal 
nerve MCV (m/s)
54.56 ± 5.14 53.63 ± 6.37 0.524
Left tibial nerve 
DML (ms)
4.06 ± 0.77 3.83 ± 0.80 0.240
Left tibial nerve 
MCV (m/s)
46.26 ± 3.75 47.38 ± 5.32 0.335
Right median 
nerve SCV (m/s)
54.93 ± 2.21 55.62 ± 3.06 0.300
Left ulnar nerve 
SCV (m/s)
58.21 ± 4.21 57.45 ± 4.09 0.469
Right sural nerve 
SCV (m/s)
51.77 ± 7.46 51.45 ± 6.83 0.859
SD, standard deviation; DML, distal motor latency; MCV, motor 
conduction velocity; SCV, sensory conduction velocity.
Table 2 – Distribution and comparison of CSP latency 
and duration measured from APB and TA muscles of 
patients and controls according to groups.
CSP (ms) Patient group 
(n = 32) 
Mean ± SD
Control group 
(n = 32)
Mean ± SD
P
Upper extremity 
Latency
Duration
87.60 ± 7.49
47.17 ± 7.33
79.77 ± 8.15
49.92 ± 9.74
0.001
0.151
Lower extremity
Latency
Duration
108.85 ± 10.03
52.91 ± 13.20
103.42 ± 10.37
55.93 ± 9.11
0.037
0.692
APB, Abductor pollicis brevis; TA, tibialis anterior; SD, standard 
deviation; CSP, cutaneous silent period.
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As a result of the comparisons, while there was no re-
lationship between prolongation of CSP latency in the up-
per extremity and the evaluation parameters, we detected 
a relationship between prolongation of CSP latency in the 
lower extremity and numbers of total symptoms, FIQ score 
and physical health level. Accordingly, there was a positive 
correlation between prolongation of CSP latency and num-
ber of total symptoms and FIQ score and a negative cor-
relation between prolongation of CSP latency and physical 
health level. 
A regression analysis done for signifi cant correlations by 
using group 1 values as the dependent variable demonstrated 
that prolongation of CSP latency in the lower extremity was 
associated with disease severity and functional disability 
measured with FIQ (odds ratio [OR]: 0.467, P = 0.002) and phys-
ical health level measured with the physical health subscale 
of SF-36 (OR: −0.231, P = 0.024). 
Discussion
Fibromyalgia (FM) is not directly associated with organ dys-
function. Various gene polymorphisms, alterations of the 
hypothalamic-pituitary-adrenal (HPA) axis, abnormal concen-
tration of neuropeptides and biogenic amines such as sero-
tonin, norepinephrine, cortisol, and substance P, and altera-
tions of activation of receptors such as N-methyl-D-aspartic 
acid (NMDA) and glutamate have been described in its etio-
pathogenesis.16 
A reduction in inhibitory mediators such as serotonin 
and an increase in excitatory mediators such as substance 
P induced by various factors of stress, trauma or infectious 
agents in genetically predisposed individuals may explain the 
symptoms, including psychological and sleep disorders and 
Table 5 – Comparisons between group 1 and group 
2 for lower extremities in terms of disease duration, 
number of total symptoms and tender points, pain level 
evaluated by VAS, FIQ score, levels of depression and 
anxiety, and quality of life.
Parameters Group 1
Normal CSP 
latency
(n = 12)
Mean ± SD
Group 2 
Prolonged CSP 
latency
(n = 20)
Mean ± SD
P
Disease duration 
(year)
5.25 ± 2.95 5.66 ± 3.11 0.708
Number of total 
symptoms 
(0-37)
21.50 ± 8.45 27.95 ± 8.42 0.045
Number of tender 
points (0-18)
15.33 ± 2.30 15.70 ± 2.10 0.649
Pain level (VAS: 
0-10 cm)
7.83 ± 1.11 8.10 ± 0.91 0.467
FIQ score (0-100) 61.50 ± 10.82 69.78 ± 7.23 0.015
Beck Depression 
Inventory level 
(0-63)
20.40 ± 11.56 21.83 ± 10.87 0.731
Beck Anxiety 
Inventory level 
(0-63)
21.83 ± 13.02 23.35 ± 11.40 0.732
Quality of life
Physical health 
level (0-100)
Mental health 
level (0-100)
27.85 ± 0.27
19.81 ± 1.54
26.16 ± 2.74
19.65 ± 1.48
0.043
0.769
CSP, cutaneous silent period; SD, standard deviation; VAS, visual 
analogue scale; FIQ, Fibromyalgia Impact Questionnaire.
Table 4 – Comparisons between group 1 and group 
2 for upper extremities in terms of disease duration, 
number of total symptoms and tender points, pain level 
evaluated by VAS, FIQ score, levels of depression and 
anxiety, and quality of life.
Parameters Group 1
Normal CSP 
latency 
(n = 4)
Mean ± SD
Group 2 
Prolonged CSP 
latency
(n = 28)
Mean ± SD
P
Disease duration 
(year)
5.25 ± 2.06 5.42 ± 3.10 0.913
Number of total 
symptoms 
(0-37)
24.92 ± 9.02 29.75 ± 7.50 0.318
Number of tender 
points (0-18)
15.50 ± 2.25 16.03 ± 1.41 0.671
Pain level (VAS: 
0-10 cm)
8.08 ± 0.45 8.11 ± 1.05 1.000
FIQ score (0-100) 66.12 ± 9.74 70.81 ± 6.98 0.364
Beck Depression 
Inventory level 
(0-63)
15.10 ± 12.72 21.78 ± 10.90 0.262
Beck Anxiety 
Inventory level 
(0-63)
18.50 ± 11.09 23.39 ± 12.01 0.069
Quality of life
Physical health 
level (0-100)
Mental health 
level (0-100)
27.06 ± 2.08
20.52 ± 1.24
24.92 ± 3.26
19.64 ± 1.51
0.062
0.278
CSP, cutaneous silent period; SD, standard deviation; VAS, visual 
analogue scale; FIQ, Fibromyalgia Impact Questionnaire.
Table 3 – Distribution of disease duration, numbers of 
total symptoms and tender points, VAS level, FIQ score, 
levels of depression and anxiety, and quality of life of 
patients.
Parameters Patient group (n = 32) Mean 
± SD
Disease duration (year) 5.40 ± 2.97
Number of total symptoms 
(0-37)
25.53 ± 8.88
Number of tender points (0-18) 15.56 ± 2.15
Pain level (VAS: 0-10 cm) 8.03 ± 0.98
FIQ score (0-100) 66.71 ± 9.48
Beck Depression Inventory level 
(0-63)
20.93 ± 11.15
Beck Anxiety Inventory level 
(0-63)
22.78 ± 11.85
Quality of life
Physical health level (0-100)
Mental health level (0-100)
26.79 ± 2.30
19.75 ± 1.49
SD, standard deviation; VAS, visual analogue scale; FIQ, Fibromyalgia 
Impact Questionnaire.
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muscle weakness.17 Inadequate levels of cortisol, growth hor-
mone and insulin-like growth factor-1 due to dysfunction of 
the HPA may cause symptoms such as fatigue and exercise 
intolerance.18
However, these theories are not suffi cient to explain the 
chronic and widespread pain in FM. The pain threshold de-
crease in FM and pain are not limited to tender point sites, and 
there is increased sensitivity to nonspecifi c stimuli such as me-
chanical pressure and cold/warm sensations in areas outside 
tender point sites or in areas without spontaneous pain. More-
over, there is an aberration of the central pain mechanisms.7,19
Studies in the literature have reported that hyperexcitabil-
ity of spinal and supraspinal neuron plays an important role 
in the development and maintenance of chronic pain.4,5
Indirect evidences such as regional increase in cerebral 
blood fl ow of some brain areas, alterations of the nociceptive 
modulating system, central sensitization, increase in tempo-
ral summation, late evoked potentials, sensitivity of C fi bers, 
and alteration in levels of substance P, which are known to 
play an effective role in the transmission of pain in patients 
with FM, have been reported in the literature.20,21
Peripheral nociceptors can be stimulated with tissue trau-
ma and/or up-regulation of nociceptor expression. Impulses 
from peripheral nociceptors are transmitted to the spinal cord 
by myelinated A delta and unmyelinated C fi bers. First pain is 
mediated by A delta fi ber, and chronic pain occurs by C fi bers 
with following continued stimulus22. Although studies evaluat-
ing C fi bers by NFR are found in the literature,22,23 only one study 
has evaluated A delta fi bers using the CSP measurement.10
Therefore, we aimed to compare patients with FM with 
healthy controls in order to evaluate any differences in CSP 
latency and duration in the upper and lower extremities, and 
if present, to determine whether any relationship exists be-
tween CSP and disease characteristics, psychological disor-
ders and quality of life. 
Based on the results of our study, while signifi cantly pro-
longed CSP latencies in both upper and lower extremities 
were found in patients compared to the control group, there 
was no signifi cant difference between groups in terms of CSP 
duration. In addition, we found that prolongation of CSP la-
tency in the lower extremity was correlated with disease se-
verity and physical functional disability of patients.
The CSP is a protective refl ex that causes a pause in vol-
untary muscle contraction in the presence of painful stimuli 
of a cutaneous nerve. The afferent impulses that generate 
the CSP are carried by A delta fi bers, but the central mecha-
nism of CSP is not known.24 The CSP is useful to evaluate the 
components and segments of A delta fi bers (not evaluated by 
modern electrodiagnostic methods) and to understand the 
central nervous system (CNS) diseases with motor and sen-
sory disorders.25 Some studies have used CSP to evaluate the 
nociceptive pathway function at spinal and supraspinal levels 
in patients with neuropathic pain.26 
Studies in the literature have shown that CSP was recorded 
in various sensory neuropathies including Friedreich’s ataxia, 
abetalipoproteinemia and Fabry disease, entrapment neurop-
athies such as carpal and ulnar tunnel syndromes, spinal cord 
lesions including myelopathy, radiculopathy, syringomyelia, 
and root avulsion, and disorders of the CNS including Par-
kinson’s disease and dystonia.25,27-31 In addition, studies have 
reported that CSP measurements can be done with various 
muscles and with different methods. A study similar to our 
study in the literature, by Sahin et al.,10 showed that CSP la-
tency recorded from the APB muscle with stimulation of the 
5th fi nger of patients with FM (n = 28) was longer than in the 
control group (n = 18), but there was no signifi cant difference 
between groups in terms of CSP duration. Further, only the 
upper extremity was evaluated in their study.
In the present study, although we used different methods 
of stimulation from those in the literature, a signifi cant pro-
longation in CSP latencies (measured in APB and TA muscles) 
in both upper and lower extremities was found in patients 
compared to controls. Moreover, there was no difference in 
terms of CSP duration. This result is compatible with that re-
ported by Sahin et al.10
Studies have reported that CSP latency occurs at three 
times: peripheral conduction time conducted by A delta fi -
bers, the time required for inhibition in the spinal cord, and 
the time from the spinal cord to muscle motor fi bers.32 Our 
results are compatible with theories that cite changes in the 
pain pathway. Studies in the literature have reported that CSP 
duration is shortened and latency increased in peripheral 
neuron disorders such as neuropathy and loss of A delta fi -
bers. Furthermore, both CSP latency and duration are extend-
ed in Parkinson’s disease and dystonia. None of our patients 
had evidence suggesting neuropathy in conduction velocity 
studies or evidence of loss of A delta fi bers such as myelopa-
thy, radiculopathy or root avulsion. Studies in Parkinson’s dis-
ease have explained that prolonged CSP duration is related to 
longer-lasting activity in inhibitory circuits in the spinal cord.
According to our results, while there was a slight shorten-
ing in CSP duration in patients when compared to the con-
trol group, the difference was not statistically signifi cant. 
Although our patients had no major disorder suggesting the 
loss of A delta fi bers, Onal et al.,33 in their study performed 
in patients with no large fi ber neuropathy with early stage 
diabetes mellitus, and Oz et al.34 in their study performed in 
patients with restless legs syndrome, reported that prolonged 
CSP latency is related to small fi ber neuropathy. Moreover, 
Ulas et al.35 evaluated the presence of dysautonomia in FM 
and showed that latency of sympathetic skin response is lon-
ger than in the control group, and they also reported that this 
result may be an indicator of small fi ber neuropathy in pa-
tients with FM. 
In light of this information, we think that our patients may 
have had a small fi ber neuropathy. However, except for the 
above-mentioned possibilities, the reason for normal CSP du-
ration may be related to technical problems during the mea-
surements.
In the literature, it has been reported that pain has two 
emotional components. Accordingly, the primary pain effect 
is the unpleasantness of the sensation, while the second-
ary pain effect is the occurrence of negative feelings like de-
pression, anger and fear.36 FM affects the psychological and 
functional emotional health as well as the quality of life of 
patients due to the chronicity of the pain. Studies about the 
pathogenesis of FM have shown that depression and anxiety 
are affected by similar neuroendocrine mechanisms.37 As a re-
sult of our study, although there was no relationship between 
CSP latency and levels of anxiety and depression, our levels 
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of anxiety and depression were above normal values. As re-
ported in the literature, these psychological disorders may be 
risk factors for the development of FM, and it is theorized that 
these disorders are present from the onset of the disease.38
Quality of life assessment instruments can be generic or 
specifi c. We used SF-36 for the generic assessment and FIQ 
for specifi c assessment. Studies in the literature have re-
ported that quality of life levels assessed by FIQ and SF-36 
in patients with FM were signifi cantly higher than in healthy 
volunteers.39,40 Our results could not be compared, since there 
is no study in the literature that investigated CSP latency in 
patients with FM. 
Pagano et al.41 evaluated the quality of life in patients with 
FM using FIQ and SF-36, and reported that FIQ is better for as-
sessing the quality of life than SF-36. This study also showed 
a limitation in physical functioning in patients with FM, re-
duced by 10-fold compared with the control group.
Our results, showing that prolongation of CSP latency is 
associated with the scores of FIQ and the physical health 
subscale of SF-36, demonstrate that the abnormality in pain 
pathways is refl ected in the physical function of the patients. 
Further, this result may be related to a potential small fi ber 
neuropathy. Considering the results discussed above, the 
presence of a potential small fi ber neuropathy in these pa-
tients may explain the lack of difference in the mental health 
according to the SF-36 subscale and the levels of anxiety and 
depression. Although large-scale studies are needed, we think 
that the evaluation of CSP latency in patients with FM may 
shed light on the functional disability of patients.
The association of CSP latency in the lower extremity 
with disease severity and limitation of physical function 
may be explained by measurements in the upper extremity 
that were carried out in the sitting position, while measure-
ments in the lower extremity were carried out in the supine 
position, which is more comfortable. Therefore, the mainte-
nance of the voluntary muscle contraction may be easier in 
the supine position than in the sitting position. Studies have 
reported that muscle distance may be effective on latency 
and duration of CSP.28,42 The effect of this refl ex increases 
from the proximal to the distal muscles. The upper extrem-
ity has a shorter refl ex pathway compared to the lower ex-
tremity in terms of limb length; therefore, functional disabil-
ity may be associated with the prolongation of CSP latency 
in the lower extremity. 
Study limitations
This study is subject to several limitations. Clinical assess-
ment scales were not implemented in the control group; thus, 
adequate comparisons could not be made. Further, no test 
such as skin biopsy or study of the autonomic nervous system 
was done to confi rm the diagnosis of small fi ber neuropathy 
in our study, thereby precluding the statement of any defi ni-
tive result. 
Conclusion
CSP latencies in both upper and lower extremities in pa-
tients with FM are longer than in healthy volunteers. We 
think that this result supports the theory of abnormalities 
in the pain pathway at peripheral and spinal levels in the 
pathogenesis of FM. These abnormalities may be due to the 
changes in the posterior horn of the spinal cord as well as to 
a small fi ber neuropathy due to a direct loss of A delta fi bers. 
To determine the exact cause, studies evaluating the A delta 
fi ber and utilizing several tests simultaneously are needed. 
As a secondary outcome, it was found that the prolongation 
of the CSP latency in the lower extremity is associated with 
disease severity and physical functional disability. Accord-
ingly, we think that CSP latency may be used as an assess-
ment method for evaluating the disease severity and physi-
cal disability in FM. However, prior to its use as a standard 
measurement method, large-scale studies should be done 
and normal values created.  
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